Stock Analysis
Intra-Cellular Therapies, Inc. (ITCI) Stock Analysis
Intra-Cellular Therapies, Inc. (ITCI) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Intra-Cellular Therapies, Inc. (ITCI) currently has an AIQ Score of 54/100, indicating a neutral setup. Risk is the strongest factor at 82/100. Value is the weakest current factor at 34/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
ITCI at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | — |
| AIQ Score | 54/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | — |
| Market Cap | $14.05B |
| P/E Ratio | -180.64 |
| Forward P/E | — |
| EPS | $0.56 |
| Revenue TTM | $199.22M |
| Dividend Yield | 0.00% |
| Beta | 0.46 |
| Volume | — |
| 52-week range | — |
| RSI 14 | — |
| 50-Day SMA | — |
| 200-Day SMA | — |
| Analyst Price Target | $132.00 |
| Next Earnings | — |
Create a free account to keep researching stocks
You have viewed 2 stock pages in the last 24 hours. Create a free account to keep researching current evidence.
ITCI
OverviewITCI Stock Analysis Summary
Intra-Cellular Therapies, Inc. (ITCI) currently has an AIQ Score of 54/100, indicating a neutral setup. Risk resilience is the strongest factor at 82/100. Value is the weakest current factor at 34/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, ITCI has AIQ Score of 54/100 with Risk resilience base of 82/100 and fading Value at 34/100. Wait for component alignment before adding exposure.
Risk resilience (82/100) leads while Value (34/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · — stock move · ITCI classified in Drug Manufacturers - Specialty & Generic.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is ITCI Bullish or Bearish Right Now?
ITCI currently has a neutral overall setup. Risk Resilience is the strongest factor at 82/100, while Value is weakest at 34/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 60/100.
- - Risk Resilience is supportive at 82/100.
- - Value is the current constraint at 34/100.
Current Consensus
ITCI's Technical Analysis Consensus is currently —, with 0 buy, 0 neutral, and 0 sell votes. ITCI's beta is 0.46, indicating lower market sensitivity than the broad market.
What Changed in ITCI?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the ITCI Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
ITCI Decision Framework
Public evidence layers, setup checks, and risk context for Intra-Cellular Therapies, Inc..
Intra-Cellular Therapies, Inc. (ITCI) Stock Analysis
Intra-Cellular Therapies, Inc. has an AIQ Score of 54/100 in a Neutral regime. Risk is strongest at 82/100. Beta is 0.46, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | ITCI is in a Neutral AIQ regime with score 54/100. |
| Signal Conflict | The primary conflict is that risk leads at 82/100 while value lags at 34/100. |
| Factor Evidence | Value 34/100 · Quality 60/100 · Risk 82/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Risk is the strongest factor at 82/100.
Momentum is —.
ITCI is in a Neutral regime at 54/100.
Risk factor is 82/100 with beta 0.46.
Current conflict: risk leads at 82/100 while value lags at 34/100.
ITCI Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
ITCI Fundamentals
ITCI valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
ITCI Technical Analysis
ITCI technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
ITCI Stock Catalysts
Track ITCI earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
ITCI Dividend Analysis
ITCI dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
ITCI Financial Data
ITCI revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
ITCI Risk Analysis
ITCI volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
ITCI Stock News
ITCI stock news, market tone, recent headlines, and catalyst context.
ITCI vs Gene Editing / Genomics / Biotech Peers
Current peer cohort: ITCI · KPTI · LEGN · MRVI · NTLA. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| ITCI Current stock | 54/100 | 34/100 | — | 82/100 | — | — | Current |
| KPTI Karyopharm Therapeutics | 61/100 | 65/100 | 27/100 | 32/100 | -0.39 | 113.60% | ITCI vs KPTI |
| LEGN Legend Biotech | 45/100 | 54/100 | 25/100 | 45/100 | -0.51 | 73.84% | ITCI vs LEGN |
| MRVI Maravai LifeSciences | 35/100 | 34/100 | 31/100 | 46/100 | 1.62 | 68.47% | ITCI vs MRVI |
| NTLA Intellia Therapeutics | 32/100 | 34/100 | 27/100 | 42/100 | 0.54 | 100.40% | ITCI vs NTLA |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 11, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Sep 12, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Dec 31, 2024.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching ITCI
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for ITCI
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
ITCI Stock FAQ
What is ITCI stock price today?
Intra-Cellular Therapies, Inc.'s current stock price is shown near the top of this overview when the latest quote is available. Use the quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is ITCI bullish or bearish right now?
ITCI's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is ITCI's market cap?
ITCI's market cap is $14.05B based on the latest completed market-close snapshot from Sep 12, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is ITCI's current P/E ratio?
ITCI's current P/E ratio is -180.64 based on the latest completed market-close snapshot from Sep 12, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is ITCI's RSI?
ITCI's RSI appears in the technical analysis view when market-close technical data is available. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is ITCI above its 50-day and 200-day moving averages?
ITCI's price versus the 50-day and 200-day moving averages helps describe trend confirmation. The overview and technicals page show this context when those moving-average fields are available.
When is ITCI's next earnings date?
ITCI's next earnings date is a key event to check before making a decision. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does ITCI pay a dividend?
ITCI's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 12, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.